SCHEMBL4446502

SCHEMBL4446502

O=C(CO)C1(c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.50
APP P05067 1/20 0.50
SLC6A3 Q01959 3/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
AKR1C1 Q04828 1/20 0.40
SLC6A4 P31645 2/20 0.40
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
SLC6A2 P23975 1/20 0.40
PTPN1 P18031 1/20 0.40
GSK3B P49841 1/20 0.40
KDM1A O60341 1/20 0.40
OPRL1 P41146 2/20 0.39
OPRM1 P35372 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578123 0.85 GSK3B (0.50) THRBAPPSLC6A3CES2CES1
SCHEMBL4435074 0.81 AKR1C3 (0.49) THRBAPPSLC6A3CES2AKR1C3
SCHEMBL4436038 0.80 APP (0.45) APPSLC6A3OPRM1HDAC1
SCHEMBL694972 0.80 APP (0.66) THRBAPPSLC6A3CES2CES1
SCHEMBL4440466 0.79 SLC6A4 (0.46) SLC6A3SLC6A4SLC6A2HDAC3HDAC1
SCHEMBL3443674 0.79 GSK3B (0.47) THRBAPPSLC6A3CES2CES1
SCHEMBL13658476 0.79 THRB (0.43) THRBAPPSLC6A3CES2CES1
SCHEMBL23578312 0.79 THRB (0.53) THRBAPPSLC6A3CES2CES1
SCHEMBL5342038 0.79 THRB (0.53) THRBAPPSLC6A3CES2CES1
SCHEMBL5007609 0.77 HSD11B1 (0.53) OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE THRB 2589/4885APP 3132/4885SLC6A3 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.